Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings

Cingulate Inc. (NASDAQ:CING) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Cingulate in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst J. Vandermosten now anticipates that the company will earn ($0.55) per share for the quarter, up from their prior estimate of ($0.57). The consensus estimate for Cingulate’s current full-year earnings is ($2.40) per share. Zacks Research also issued estimates for Cingulate’s FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.30) EPS and FY2028 earnings at ($1.02) EPS.

Cingulate (NASDAQ:CING) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.18.

CING has been the topic of a number of other research reports. Roth Capital reissued a “buy” rating and issued a $10.00 price target on shares of Cingulate in a research note on Tuesday, May 19th. Ascendiant Capital Markets reduced their price objective on shares of Cingulate from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Wall Street Zen raised shares of Cingulate from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Cingulate in a research report on Tuesday, May 26th. Finally, Weiss Ratings cut shares of Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.33.

Cingulate Price Performance

Shares of CING stock opened at $5.33 on Friday. The company has a market cap of $77.50 million, a price-to-earnings ratio of -1.48 and a beta of -0.90. The stock has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $5.58. Cingulate has a 1-year low of $3.16 and a 1-year high of $11.89.

Institutional Trading of Cingulate

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Cingulate by 283.1% during the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock worth $31,000 after purchasing an additional 5,543 shares in the last quarter. Soltis Investment Advisors LLC purchased a new position in Cingulate in the 4th quarter valued at $43,000. XTX Topco Ltd acquired a new stake in Cingulate during the 2nd quarter worth $45,000. Quadrature Capital Ltd purchased a new stake in shares of Cingulate during the fourth quarter worth $66,000. Finally, Kestra Advisory Services LLC grew its holdings in shares of Cingulate by 14.8% during the first quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock worth $869,000 after buying an additional 18,000 shares in the last quarter. 41.31% of the stock is owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.